China’s Creat suffers setback in Biotest deal on U.S. scrutiny

FRANKFURT (Reuters) - Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma prod…
Read the full story: Reuters: Health News